RSV Prevention, Part IV: Immunocompromised Populations
Avalere Essential Voice
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
info_outline
RSV Prevention, Part III: Older Adult Vaccination
Avalere Essential Voice
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, experts discuss the future of RSV among older adults.
info_outline
RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Avalere Essential Voice
Tune into the second episode in our miniseries focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
info_outline
RSV Prevention, Part I: Pediatric Monoclonal Antibodies
Avalere Essential Voice
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
info_outline
NCDs, Part III: Agency Mandates, Decisions, Coverage, and Access
Avalere Essential Voice
Tune into the third episode in the Health Essential Voice podcast series focused on Agency decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs) by considering how potential policy and market catalysts 3 to 5 years out may help stakeholders think through opportunities and risks at key decision points ranging from early in development to implications for Part D.
info_outline
NCDs, Part II: Evidence Development to Fulfill CED Requirements
Avalere Essential Voice
Tune into the second episode in the Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.
info_outline
NCDs, Part I: Overview of NCDs, CED, and Potential Access Barriers
Avalere Essential Voice
Tune into the first episode in the Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.
info_outline
Exploring the Kidney Care Environment, Part III: Addressing Healthcare Disparities
Avalere Essential Voice
In the third and final episode of the Avalere Health Essential Voice miniseries focused on kidney care, our experts share insights on disparities in kidney care. Listen to previous episodes in this series:
info_outline
Exploring the Kidney Care Environment, Part II: Policy and Payment Trends
Avalere Essential Voice
In the second episode of the Avalere Health Essential Voice miniseries focused on kidney care, our experts share their perspective on policy and payment trends. Listen to previous episodes in this series:
info_outline
Intro to the Kidney Care Environment: Key Players, Treatment, and Payment Systems
Avalere Essential Voice
In this episode of Health Essential Voice, we kick off our miniseries focused on the evolving kidney care landscape.
info_outlineIn this episode of the Avalere Health Essential Voice Disease Education series, our experts discuss Huntington’s Disease through the lens of its symptoms, challenges, and potential treatment.